Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5442-5453

  Gorlick, Richard ^a   Anderson, Peter ^b   Andrulis, Irene ^c   Arndt, Carola ^b   Beardsley, G Peter ^d   Bernstein, Mark ^e   Bridge, Julia ^f   Cheung, Nai Kong ^a   Dome, Jeffrey S ^g   Ebb, David ^h   Gardner, Thomas ⁱ   Gebhardt, Mark ^h   Grier, Holcombe ^j   Hansen, Marc ^k   Healey, John ^a   Helman, Lee ^l   Hock, Janet ⁱ   Houghton, Janet ^g   Houghton, Peter ^g   Huvos, Andrew ^a   Khanna, Chand ^l   Kieran, Mark ^j   Kleinerman, Eugenie ^m   Ladanyi, Marc ^a   Lau, Ching ⁿ   Malkin, David ^o   Marina, Neyssa ^p   Meltzer, Paul ^a   Meyers, Paul ^a   Schofield, Deborah ^q   Schwartz, Cindy ^r   Smith, Malcolm A ^l   Toretsky, Jeffrey ^s   Tsokos, Maria ^l   Wexler, Leonard ^a   Wigginton, Jon ^l   Withrow, Stephen ^t   Schoenfeldt, Mason ^u   Anderson, Barry ^l   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MONTREAL   (Canada)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^l NATIONAL CANCER INSTITUTE   (United States)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ BAYLOR COLLEGE OF MEDICINE   (United States)

^o HOSPITAL FOR SICK CHILDREN   (Canada)

^p STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^q CHILDREN S HOSPITAL LOS ANGELES   (United States)

^r JOHNS HOPKINS HOSPITAL   (United States)

^s GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^t Department of Environmental and Radiological Health Sciences   (United States)

^u EMMES CORPORATION   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FOLIC ACID ANTAGONIST; GLYCOPROTEIN P; GROWTH HORMONE; SOMATOMEDIN C;

ANGIOGENESIS; BONE CANCER; CANCER INHIBITION; CELL DEATH; CHILD; CONFERENCE PAPER; GENE EXPRESSION; HUMAN; NORTH AMERICA; OSTEOSARCOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNITED STATES; VIRUS PATHOGENESIS;

EID: 0344198135     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (127)

1. Mitelman, F. Recurrent chromosome aberrations in cancer. Mutat. Res., 462: 247-253, 2000.
2. Bridge, J. A., Nelson, M., McComb, E., McGuire, M. H., Rosenthal, H., Vergara, G., Maale, G. E., Spanier, S., and Neff, J. R. Cytogenetic findings in 73 osteosarcoma specimens and a review of the literature. Cancer Genetics Cytogenetics, 95: 74-87, 1997.
3. Boehm, A. K., Squire, J. A., Bayani, J., Nelson, M., Neff, J. R., and Bridge, J. A. Cytogenetic findings in 36 osteosarcoma specimens and a review of the literature. Ped. Pathol. Mol. Med., 19: 359-376, 2000.
4. Gisselsson, D., Palsson, E., Hoglund, M., Domanski, H., Mertens, F., Pandis, N., Sciot, R., Dal Cin, P., Bridge, J. A., and Mandahl, N. Differentially amplified chromosome 12 sequences in low- and highgrade osteosarcoma. Genes Chromosomes Cancer, 33: 133-140, 2002.
5. Raymond, A. K., Ayala, A. G., and Knuutila, S. Conventional Osteosarcoma. In: P. Kleihues, L. Sobin, C. Fletcher, K. Unni, and F. Mertens (eds.), WHO Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone, pp. 267-269. Lyon, France: IARC Press, 2002.
6. Bayani, J., Zielenska, M., Pandita, A., Al-Romaih, K., Karaskova, J., Harrison, K., Bridge, J. A., Sorensen, P., Thorner, P., and Squire, J. A. SKY identifies recurrent complex rearrangements involving chromo somes 8, 17, and 20 in osteosarcomas. Genes Chromosome Cancer, 36: 7-16, 2003.
7. Ladanyi, M., and Gorlick, R. Molecular pathology and molecular pharmacology of osteosarcoma. Pediatr. Pathol. Mol. Med., 19: 391-413, 2000.
8. Kruzelock, R. P., and Hansen, M. F. Molecular genetics and cytogenetics of sarcomas. Hematology - Oncology Clin. N. Am., 9: 513-540, 1995.
9. Kruzelock, R. P., Murphy, E. C., Strong, L. C., Naylor, S. L., and Hansen, M. F. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res., 57: 106-109, 1997.
10. Nellissery, M. J., Padalecki, S. S., Brkanac, Z., Singer, F. R., Roodman, G. D., Unni, K. K., Leach, R. J., and Hansen, M. F. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am. J. Hum. Genet., 63: 817-824, 1998.
11. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Jr., Nelson, C. E., Kim, D. H., Eassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Wash. DC), 250: 1233-1238. 1990
12. Quesnel, S., and Malkin, D. Genetic predisposition to cancer and familial cancer syndromes. Ped. Clin. N. Am., 44: 791-808, 1997.
13. Malkin, D. The role of p53 in human cancer. J. Neuro-Oncol., 51: 231-243, 2001.
14. Wei, G., Lonardo, F., Ueda, T., Kim, T., Huvos, A. G., Healey, J. H., and Ladanyi, M. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons, Int. J. Cancer, 80: 199-204, 1999.
15. Gokgoz, N., Wunder, J. S., Mousses, S., Eskandarian, S., Bell, R. S., and Andrulis, I. L. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer (Phila.), 92: 2181-2189, 2001.
16. Yamaguchi, T., Toguchida, J., Yamamuro, T., Kotoura, Y., Takada, N., Kawaguchi, N., Kaneko, Y., Nakamura, Y., Sasaki, M. S., and Ishizaki, K. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res., 52: 2419-2423, 1992.
17. Tarkkanen, M., Karhu, R., Kallioniemi, A., Elomaa, I., Kivioja, A. H., Nevalainen, J., Bohling, T., Karaharju, E., Hyytinen, E., Knuutila, S. et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization, Cancer Res., 55: 1334-1338, 1995.
18. Hoogerwerf, W. A., Hawkins, A. L., Perlman, E. J., and Griffin, C. A. Chromosome analysis of nine osteosarcomas. Genes, Chromosomes Cancer, 9: 88-92, 1994.
19. Bianco, P., Riminucci, M., Gronthos, S., and Robey, P. Bone marrow stromal cells: nature, biology and ptoential applications. Stem Cells, 19: 180-192, 2001.
20. Ohyama, K., Chung, C. H., Chen, E., Gibson, C. W., Misof, K., Fratzl, P., and Shapiro, I. M. p53 influences mice skeletal development. J.Craniofacial Genet. Dev. Biol., 17: 161-171, 1997.
21. Vahle, J., Sato, M., Long, G., Young, J., Francis, P., Engelhardt, J., Westmore, M., Ma, Y., and Nold, J. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol., 30: 312-321. 2002.
22. Milas, J., Stanislaus, D., Ohashi, N., Pulcini, J., Murthy, S., Leyvand, I., Dunn-Jena, P., and Hock, J. In vivo, p53 contributes to the anabolic effect of PTH by controlling the magnitude of AP-1 gene expression, Ann. Mtg. Endocr. Soc., 2001.
23. Stanislaus, D., Yang, X., Liang, J., Wolfe, J., Cain, R., Onyia, J., Falla, N., Marder, P., Bidwell, J., Queener, S., and Hock, J. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone, hPTH 1-34 fragment. Bone, 27: 209-218, 2000.
24. Artandi, S. E., Chang, S., Lee, S. L., Alson, S., Gottlieb, G. J., Chin, L., and DePinho, R. A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature (Lond.), 406: 641-645, 2000.
25. Harley, C. B. Telomere loss: mitotic clock or genetic time bomb? Mutat. Res., 256: 271-282, 1991.
26. Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C. P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., and Wright, W. E. Extension of life-span by introduction of telomerase into normal human cells. [comment]. Science (Wash. DC), 279: 349-352, 1998.
27. Shay, J. W., and Bacchetti, S. A survey of telomerase activity in human cancer. Eur. J. Cancer, 33: 787-791, 1997.
28. Bryan, T. M., Englezou, A., Dalla-Pozza, L., Dunham, M. A., and Reddel, R. R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med., 3: 1271-1274, 1997.
29. Scheel, C., Schaefer, K. L., Jauch, A., Keller, M., Wai, D., Brinkschmidt, C., van Valen, F., Boecker, W., Dockhorn-Dworniczak, B., and Poremba, C. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene, 20: 3835-3844, 2001.
30. Aue, G., Muralidhar, B., Schwartz, H. S., and Butler, M. G. Telomerase activity in skeletal sarcomas. Ann. Surg. Oncol., 5: 627-634, 1998.
31. Sangiorgi, L., Gobbi, G. A., Lucarelli, E., Sartorio, S. M., Mordenti, M., Ghedini, I., Maini, V., Scrimieri, F., Reggiani, M., Bertoja, A. Z., Benassi, M. S., and Picci, P. Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int. J. Cancer, 95: 156-161, 2001.
32. Chang, S., Khoo, C. M., Naylor, M. L., Maser, R. S., and DePinho, R. A. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression (Published erratum appears in Genes Dev., 17: 541, 2003]. Genes Dev., 17: 88-100, 2003.
33. Chang, S., Khoo, C. M., Naylor, M. L., Maser, R. S., and DePinho, R. A. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression (Published erratum appears in Genes Dev., 17: 541, 2003]. Genes Dev., 17: 88-100, 2003.
34. Carbone, M., Rizzo, P., Procopio, A., Giuliano, M., Pass, H. I., Gebhardt, M, C., Mangham, C., Hansen, M., Malkin, D. F., Bushart, G., Pompetti, F., Picci, P., Levine, A. S., Bergsagel, J. D., and Garcea, R, L. SV40-like sequences in human bone tumors. Oncogene, 13: 527-535, 1996.
35. Mendoza, S. M., Konishi, T., and Miller, C. W. Integration of SV40 in human osteosarcoma DNA. Oncogene, 17: 2457-2462, 1998.
36. Lednicky, J. A., Stewart, A. R., Jenkins, J. J., 3rd, Finegold, M. J., and Butel, J. S. SV40 DNA in human osteosarcomas shows sequence variation among T-antigen genes. Int. J. Cancer, 72: 791-800, 1997.
37. Malkin, D., Chilton-MacNeill, S., Meister, L. A., Sexsmith, E., Diller, L., and Garcea, R. L. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene, 20: 4441-4449, 2001.
38. Lefevre, S. H., Vogt, N., Dutrillaux, A. M., Chauveinc, L., Stoppa-Lyonnet, D., Doz, F., Desjardins, L., Dutrillaux, B., Chevillard, S., and Malfoy, B. Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma. Oncogene, 20: 8092-8099, 2001.
39. Poulaki, V., Mitsiades, N., Romero, M. E., and Tsokos, M. Fasmediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res., 61: 4864-4872, 2001.
40. Mitsiades, N., Poulaki, V., Mitsiades, C., and Tsokos, M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res., 61: 2704-2712, 2001.
41. Hewitt, R. E., McMarlin, A., Kleiner, D., Wersto, R., Martin, P., Tsokos, M., Stamp, G. W., Stetler-Stevenson, W. G., and Tsoskas, M. Validation of a model of colon cancer progression (Published erratum appears in J. Pathol., 194: 507, 2001). J. Pathol., 192: 446-454, 2000.
42. Hewitt, R. E., McMarlin, A., Kleiner, D., Wersto, R., Martin, P., Tsokos, M., Stamp, G. W., Stetler-Stevenson, W. G., and Tsoskas, M. Validation of a model of colon cancer progression (Published erratum appears in J. Pathol., 194: 507, 2001). J. Pathol., 192: 446-454, 2000.
43. Mitsiades, N., Poulaki, V., Mastorakos, G., Tseleni-Balafouta, S. T., Kotoula, V., Koutras, D. A., and Tsokos, M. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J. Clin. Endocrinol. Metab., 84: 2924-2932, 1999.
44. Mitsiades, N., Poulaki, V., Leone, A., and Tsokos, M. Fas-mediated apoptosis in Ewing's sarcoma cell lines by metalloproteinase inhibitors. J. Natl. Cancer Instit., 91: 1678-1684, 1999.
45. Worth, L. L., Lafleur, E. A., Jia, S. F., and Kleinerman, E. S. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol. Rep., 9: 823-827, 2002.
46. Jia, S. F., Worth, L. L., and Kleinerman, E. S. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin. Exp. Metastasis, 17: 501-506, 1999.
47. Worth, L. L., Jia, S. F., Zhou, Z., Chen, L., and Kleinerman, E. S. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res., 6: 3713-3718, 2000.
48. Latleur, E. A., Jia, S. F., Worth, L. L., Zhou, Z., Owen-Schaub, L. B., and Kleinerman, E. S. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res., 61: 4066-4071, 2001.
49. Jia, S. F., Worth, L. L., Densmore, C. L., Xu, B., Zhou, Z., and Kleinerman, E. S. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther., 9: 260-266, 2002.
50. Meyers, P., and Gorlick, R. Osteosarcoma. Ped. Clin. N. Am., 44: 973-989, 1997.
51. Wigginton, J. M., and Wiltrout, R. H. IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Exp. Opin. Biol. Ther., 2: 513-524, 2002.
52. Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J., and Wiltrout, R. H. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst., 88: 38-43, 1996.
53. Wigginton, J. M., Park, J. W., Gruys, M. E., Young, H. A., Jorcyk, C. L., Back, T. C., Brunda, M. J., Strieter, R. M., Ward, J., Green, J. E., and Wiltrout, R. H. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration. Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J. Immunol., 166: 1156-1168, 2001.
54. Wigginton, J. M., Gruys, E., Geiselhart, L., Subleski, J., Komschlies, K. L., Park, J. W., Wiltrout, T. A., Nagashima, K., Back, T. C., and Wiltrout, R. H. IFN-γ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy, J. Clin. Investig., 108: 51-62, 2001.
55. Meyers, P. A., and Gorlick, R. Osteosarcoma. Ped. Clin. N. Am., 44: 973-989, 1997.
56. Takeshita, H., Kusuzaki, K., Ashihara, T., Gebhardt, M. C., Mankin, H. J., and Hirasawa, Y. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells. J. Bone Joint Surg.-Am. Vol., 82-A: 963-969, 2000.
57. Baldini, N., Scotlandi, K., Barbanti-Brodano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M. et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome [comment]. N. Eng. J. Med., 333: 1380-1385, 1995.
58. Takeshita, H., Gebhardt, M. C., Springfield, D. S., Kusuzaki, K., and Mankin, H. J. Experimental models for the study of drug resistance in osteosarcoma: P-glycoprotein-positive, murine osteosarcoma cell lines. J. Bone Joint Surg.-Am. Vol., 78: 366-375, 1996.
59. Baldini, N., Scotlandi, K., Serra, M., Kusuzaki, K., Shikita, T., Manara, M. C., Maurici, D., and Campanacci, M. Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma. J. Cancer Res. Clin. Oncol., 119: 121-126, 1992.
60. Wunder, J. S., Bell, R. S., Wold, L., and Andrulis, I. L. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J. Orthopaed. Res., 11: 396-403, 1993.
61. Baldini, N., Scotlandi, K., Serra, M., Picci, P., Bacci, G., Sottili, S., and Campanacci, M. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. J. Orthopaed. Res., 17: 629-632, 1999.
62. Stein, U., Wunderlich, V., Haensch, W., and Schmidt-Peter, P. Expression of the mdrl gene in bone and soft tissue sarcomas of adult patients. Eur. J. Cancer, 29A: 1979-1981, 1993.
63. Posl, M., Amling, M., Grahl, K., Hentz, M., Ritzel, H., Werner, M., Winkler, K., and Delling, G. P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study. Gen. Diag. Pathol., 142: 317-325, 1997.
64. Chan, H. S., Grogan, T. M., Haddad, G., DeBoer, G., and Ling, V. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J. Natl. Cancer Inst., 89: 1706-1715, 1997.
65. Wunder, J. S., Bull, S. B., Aneliunas, V., Lee, P. D., Davis, A. M., Beauchamp, C. P., Conrad, E, U., Grimer, R. J., Healey, J. H., Rock, M. J., Bell, R. S., and Andrulis, I. L. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J. Clin. Oncol., 18: 2685-2694, 2000.
66. Bodey, B., Taylor, C. R., Siegel, S. E., and Kaiser, H. E. Immunocytochemical observation of multidrug resistance (MDR) p170 glyco-protein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression, Anticancer Res., 15: 2461-2468, 1995.
67. Schwartz, C. L., Gorlick, R. G., Teot, L. A., Grier, H. E., Krailo, M., and Meyers, P. A. A prospective study of p-glycoprotein (P-GP) expression in newly diagnosed non-metastatic osteosarcoma: An intergroup study of the Children's Cancer Group and the Pediatric Oncology Group. Proc. Am. Soc. Clin. Oncol., 19: 587a, 2000.
68. Scotlandi, K., Manara, M. C., Serra, M., Benini, S., Maurici, D., Caputo, A., De Giovanni, C., Lollini, P. L., Nanni, P., Picci, P., Campanacci, M., and Baldini, N. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells. Oncogene, 18: 739-746, 1999.
69. Bush, J. A., and Li, G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int. J. Cancer, 98: 323-330, 2002.
70. Banerjee, D., Mayer-Kuckuk, P., Capiaux, G., Budak-Alpdogan, T., Gorlick, R., and Bertino, J. R. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim. Biophys. Acta., 1587: 164-173, 2002.
71. Guo, W., Healey, J. H., Meyers, P. A., Ladanyi, M., Huvos, A. G., Bertino, J. R., and Gorlick, R. Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res., 5: 621-627, 1999.
72. Yang. R., Sowers, R., Mazza, B., Healey, J, H., Huvos, A., Grier, H., Bernstein, M., Beardsley, G. P., Krailo, M. D., Devidas, M., Bertino, J. R., Meyers, P. A., and Gorlick, R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin. Cancer Res., 9: 837-844, 2003.
73. Bacci, G., Ferrari, S., Delepine, N., Bertoni, F., Picci, P., Mercuri, M., Bacchini, P., Brach del Prever, A., Tienghi, A., Comandone. A., and Campanacci, M. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin [comment]. J. Clin. Oncol., 16: 658-663, 1998,
74. Delepine, N., Delepine, G., Bacci, G., Rosen, G., and Desbois, J. C. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer (Phila.), 78: 2127-2135, 1996.
75. Trippett, T., Meyers, P., Gorlick, R., Steinherz, P., Wollner, N., and Bertino, J. R. High dose trimetrexate with leucovorin protection in recurrent childhood malignancies: A Phase II trial. Proc. Am. Soc. Clin. Oncol., 18: 231a, 1999.
76. Wolf, M., El-Rifai, W., Tarkkanen, M., Kononen, J., Serra, M., Eriksen, E. F., Elomaa, I., Kallioniemi, A., Kallioniemi, O. P., and Knuutila, S. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet. Cytogenet., 123: 128-132, 2000.
77. Khan, J., Wei, J. S., Ringner, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., and Meltzer, P. S. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med., 7: 673-679, 2001.
78. Oda, Y., Naka, T., Takeshita, M., Iwamoto, Y., and Tsuneyoshi, M. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum. Pathol., 31: 709-716, 2000.
79. Ferracini, R., Angelini, P., Cagliero, E., Linari, A., Martano, M., Wunder, J., and Buracco, P. MET oncogene aberrant expression in canine osteosarcoma. J. Orthopaed. Res., 18: 253-256, 2000.
80. Zielenska, M., Bayani, J., Pandita, A., Toledo, S., Marrano, P., Andrade, J., Petrilli, A., Thorner, P., Sorensen, P., and Squire, J. A. Comparative genomic hybridization analysis identifies gains of lp35 approximately p36 and chromosome 19 in osteosarcoma. Cancer Genet. Cytogenet., 130: 14-21, 2001.
81. Ozaki, T., Neumann, T., Wai, D., Schafer, K. L., van Valen, F., Lindner, N., Scheel, C., Bocker, W., Winkelmann, W., Dockhorn-Dworniczak, B., Horst, J., and Poremba, C. Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping. Cancer Genet. Cytogenet., 140: 145-152, 2003.
82. Houghton, P. J., Adamson, P. C., Blaney, S., Fine, H. A., Gorlick, R., Haber, M., Helman, L., Hirschfeld, S., Hollingshead, M. G., Israel, M. A., Lock, R. B., Maris, J. M., Merlino, G., Patterson, W., Reynolds, C. P., Shannon, K., Yu, A., Yu, J., and Smith, M. A. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin. Cancer Res., 8: 3646-3657, 2002.
83. Thompson, J., Stewart, C. F., and Houghton, P. J. Animal models for studying the action of topoisomerase I targeted drugs. Biochim. Biophys. Acta., 1400: 301-319, 1998.
84. Khanna, C., Prehn, J., Yeung, C., Caylor, J., Tsokos, M., and Helman, L. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis, 18: 261-271, 2000.
85. Khanna, C., Khan, J., Nguyen, P., Prehn, J., Caylor, J., Yeung, C., Trepel, J., Meltzer, P., and Helman, L. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res., 61: 3750-3759, 2001.
86. Withrow, S. J., Powers, B. E., Straw, R. C., and Wilkins, R. M. Comparative aspects of osteosarcoma. Dog versus man, Clin. Orthopaed. Rel. Res., 270: 159-68, 1991.
87. Withrow, S. J. Osteosarcoma. Veterinary Quarterly, 20: S19-S21, 1998.
88. Mendoza, S., Konishi, T., Dernell, W. S., Withrow, S. J., and Miller, C. W. Status of the p53. Rb and MDM2 genes in canine osteosarcoma. Anticancer Res., 18: 4449-4453, 1998.
89. Enneking, W., Spanier, S., and Goodman, M. A system for the surgical staging of musculoskeletal sarcoma. Clin. Orthop., 153: 106-120, 1980.
90. Withrow, S. J., Thrall, D. E., Straw, R. C., Powers, B. E., Wrigley, R. H., Larue, S. M., Page, R. L., Richardson, D. C., Bissonette, K. W., Betts, C. W. et al. Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma. Cancer (Phila.), 71: 2484-2490, 1993.
91. Khanna, C., Prehn, J., Hayden, D., Cassaday, R., D., Caylor, J., Jacob, S., Bose, S. M., Hong, S. H., Hewitt, S. M., and Helman, L. J. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin. Cancer Res., 8: 2406-2412, 2002.
92. Pollak, M., Sem, A. W., Richard, M., Tetenes, E., and Bell, R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J. Natl. Cancer Inst., 84: 966-971, 1992.
93. Raile, K., Hoflich, A., Kessler, U., Yang, Y., Pfuender, M., Blum, W. F., Kolb, H., Schwarz, H. P., and Kiess, W. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor. J. Cell. Physiol., 159: 531-541, 1994.
94. Toretsky, J. A., Steinberg, S. M., Thakar, M., Counts, D., Pironis, B., Parente, C., Eskenazi, A., Helman, L., and Wexler, L. H. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer (Phila.), 92: 2941-2947, 2001.
95. Mansky, P. J., Liewehr, D. J., Steinberg, S. M., Chrousos, G. P., Avila, N. A., Long, L., Bernstein, D., Mackall, C. L., Hawkins, D. S., and Helman, L. J. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J. Ped. Hematol./Oncol., 24: 440-446, 2002.
96. Kamada, T., Tsujii, H., Tsuji, H., Yanagi, T., Mizoe, J. E., Miyamoto, T., Kato, H., Yamada, S., Morita, S., Yoshikawa, K., Kandatsu, S., Tateishi, A., Working Group for the, B., and Soft Tissue, S. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J. Clin. Oncol., 20: 4466-4471, 2002.
97. Machak, G. N., Tkachev, S. I., Solovyev, Y. N., Sinyukov, P. A., Ivanov, S. M., Kochergina, N. V., Ryjkov, A. D., Tepliakov, V. V., Bokhian, B. Y., and Glebovskaya, V. V. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clinic Proc., 78: 147-155, 2003.
98. Anderson, P. M., Wiseman, G. A., Dispenzieri, A., Arndt, C. A., Hartmann, L. C., Smithson, W. A., Mullan, B. P., and Bruland, O. S. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J. Clin. Oncol., 20: 189-196, 2002.
99. Anderson, P. M. Radiotherapy is effective for osteosarcoma responding to chemotherapy (editorial)., Mayo Clinic Proc., 2003.
100. Lawrence, T. S., Eisbruch, A., McGinn, C. J., Fields, M. T., and Shewach, D. S. Radiosensitization by gemcitabine. Oncology (Huntingt.), 13: 55-60, 1999.
101. Eisbruch, A., Shewach, D. S., Bradford, C. R., Littles, J. F., Teknos, T. N., Chepeha, D. B., Marentette, L. J., Terrell, J. E., Hogikyan, N. D., Dawson, L. A., Urba, S., Wolf, G. T., and Lawrence, T. S. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J. Clin. Oncol., 19: 792-799, 2001.
102. McGinn, C. J., and Lawrence, T. S. Recent advances in the use of radiosensitizing nucleosides. Semin. Radiat. Oncol., 11: 270-280, 2001.
103. Haydon, R. C., Zhou, L., Feng, T., Breyer, B., Cheng, H., Jiang, W., Ishikawa, A., Peabody, T., Montag, A., Simon, M. A., and He, T. C. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin. Cancer Res., 8: 1288-1294, 2002.
104. Modak, S., Kramer, K., Gultekin, S. H., Guo, H. F., and Cheung, N. K. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res., 61: 4048-4054, 2001.
105. Cheung, N. K., Modak, S., Vickers, A., and Knuckles, B. Orally administered β-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol. Immunother., 51: 557-564, 2002.
106. Krause, A., Guo, H. F., Latouche, J. B., Tan, C., Cheung, N. K., and Sadelain, M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med., 188: 619-626, 1998.
107. Matsubara, S., Wada, Y., Gardner, T. A., Egawa, M., Park, M. S., Hsieh, C. L., Zhau, H. E., Kao, C., Kamidono, S., Gillenwater, J. Y., and Chung, L. W. A conditional replication-competent adenoviral vector. Ad-OC-Ela, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res., 61: 6012-6019, 2001.
108. Shirakawa, T., Ko, S. C., Gardner, T, A., Cheon, J., Miyamoto, T., Gotoh, A., Chung, L. W., and Kao, C. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther., 5: 274-280, 1998.
109. Cheon, J., Ko, S. C., Gardner, T. A., Shirakawa, T., Gotoh, A., Kao, C., and Chung, L. W. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther., 4: 359-365, 1997.
110. Kubo, H., Gardner, T. A., Wada, Y., Koeneman, K. S., Gotoh, A., Yang, L., Kao, C., Lim, S. D., Amin, M. B., Yang, H., Black, M. E., Matsubara, S., Nakagawa, M., Gillenwater, J. Y., Zhau, H. E., and Chung, L. W. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther., 14: 227-241, 2003.
111. Anderson, P. M., Markovic, S. N., Sloan, J. A., Clawson, M. L., Wylam, M., Arndt, C. A., Smithson, W. A., Burch, P., Gomet, M., and Rahman, E. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin. Cancer Res., 5: 2316-2323, 1999.
112. Withrow, S. J., and Straw, R. C. Effects of cis-diamminedichloroplatinum II released from D. L-polylactic acid implanted adjacent to cortical allografts in dogs. Vet. Surg., 23: 341-346, 1994.
113. Dernell, W. S., Withrow, S. J., Straw, R. C., Powers, B. E., Drekke, J. H., and Lafferty, M. Intracavitary treatment of soft tissue sarcomas in dogs using cisplatin in a biodegradable polymer. Anticancer Res., 17: 4499-505, 1997.
114. Lana, S. E., Dernell, W. S., LaRue, S. M., Lafferty, M. J., Douple, E. B., Brekke, J. H., and Withrow, S. J. Slow release cisplatin combined with radiation for the treatment of canine nasal tumors. Vet. Radiol. Ultrasound, 38: 474-478, 1997.
115. Allgrove, J. Use of bisphosphonates in children and adolescents. J. Pediatric Endocrinol. Metab. 15 (Suppl. 3): 921-928, 2002.
116. Giuliani, N., Pedrazzoni, M., Passeri, G., and Girasole, G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol., 27: 38-41, 1998.
117. Diel, L. J., Meyberg, G. C., Gollan, C., Bode, S., Wallwiener, D., and Bastert, G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. Breast Cancer Res. Treat., 49: 145-154, 1998.
118. Diel, I. J., Solomayer, E. F., and Bastert, G. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer (Phila.), 88: 3080-3088, 2000.
119. Diel, I. J. Bisphosphonates in the prevention of bone metastases: current evidence. Semin. Oncol., 28: 75-80, 2001.
120. Ecklund, K., Laor, T., Goorin, A. M., Connolly, L. P., and Jaramillo, D. Methotrexate osteopathy in patients with osteosarcoma. Radiology, 202: 543-547, 1997.
121. Healey, J. The epidemic of chemotherapy-related osteoporosis. Curr. Opin. Orthop., 10: 331-333, 1999.
122. Pfeilschifter, J., and Diel, I. J. Osteoporosis due to cancer treatment: pathogenesis and management. J. Clin. Oncol., 18: 1570-1593, 2000.
123. Brumsen, C., Hamdy, N. A., and Papapoulos, S. E. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis, Medicine, 76: 266-283, 1997.
124. Kerbel, R., Viloria-Petit, A., Klement, G., and Rak, J. 'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur. J. Cancer, 36: 1248-1257, 2000.
125. Gately, S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev., 19: 19-27, 2000.
126. Stempak, D., Gammon, J., Klein, J., Moriarty, P., Halton, J., Koren, G., and Baruchel, S. Safety and pharmacokinetics of celecoxib when combined with metronomic administration of low dose chemotherapy for anti-angiogenic therapy of pediatric recurrent solid tumors. In: Proc. Am. Assoc. Cancer Res., 42: 19A, 2001.
127. Stempak, D., Gammon, J., Klein, J., Koren, G., and Baruchel, S. Single-dose and steady-state pharmacokinetics of celecoxib in children. Clin. Pharmacol. Ther., 72: 490-497, 2002.